Among the major topics at the conference this week will be the impact on global biopharma of the upcoming Trump administration, frenetic activity in the obesity field, and hopes of increased funding for UK biotech companies.
The Jefferies London Healthcare Conference is now in its 15th year, and is firmly established as Europe’s biggest biopharma investment meeting. Here are some key themes to watch out for at the event, held from Tuesday 19 November to Thursday 21 November.
Shares of big pharma and biotech companies were hit late last week when US President-elect Donald Trump named Robert F...
Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.
SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.
The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.
The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.
The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.
